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Abstract
With over 117 million COVID-19–positive cases declared and the death count approaching 3 million, we would expect that the
highly digitalized health systems of high-income countries would have collected, processed, and analyzed large quantities of
clinical data from patients with COVID-19. Those data should have served to answer important clinical questions such as: what
are the risk factors for becoming infected? What are good clinical variables to predict prognosis? What kinds of patients are more
likely to survive mechanical ventilation? Are there clinical subphenotypes of the disease? All these, and many more, are crucial
questions to improve our clinical strategies against the epidemic and save as many lives as possible. One might assume that in
the era of big data and machine learning, there would be an army of scientists crunching petabytes of clinical data to answer these
questions. However, nothing could be further from the truth. Our health systems have proven to be completely unprepared to
generate, in a timely manner, a flow of clinical data that could feed these analyses. Despite gigabytes of data being generated
every day, the vast quantity is locked in secure hospital data servers and is not being made available for analysis. Routinely
collected clinical data are, by and large, regarded as a tool to inform decisions about individual patients, and not as a key resource
to answer clinical questions through statistical analysis. The initiatives to extract COVID-19 clinical data are often promoted by
private groups of individuals and not by health systems, and are uncoordinated and inefficient. The consequence is that we have
more clinical data on COVID-19 than on any other epidemic in history, but we have failed to analyze this information quickly
enough to make a difference. In this viewpoint, we expose this situation and suggest concrete ideas that health systems could
implement to dynamically analyze their routine clinical data, becoming learning health systems and reversing the current situation.
(JMIRx Med 2021;2(2):e20617) doi: 10.2196/20617
KEYWORDS
COVID-19; learning health systems
JMIRx Med 2021 | vol. 2 | iss. 2 | e20617 | p. 1https://xmed.jmir.org/2021/2/e20617
(page number not for citation purposes)




Many countries reacted late to the spread of the COVID-19
pandemic, although once they realized the seriousness of the
situation, they took strong measures. The best-known measures
relate to restrictions on population movement; other important
implementations include increasing the capacity of health
systems and the mobilization of the military to aid in this health
emergency. Using a martial simile, it appears that governments
have prepared their “health” armies and their populations for
the war against the virus.
An additional necessity is a good intelligence service to fight
the war. This requires a system to collect data on the enemy
and a group of analysts who can extract relevant information.
Most current information systems pertaining to the pandemic
focus on counting numbers of individuals tested, infected,
hospitalized with serious conditions, recovered, and deceased.
Data have also been collected to understand public behaviors
[1], some of which was planned for [2]. These kinds of data can
serve to estimate epidemiological curves and predict how the
pandemic might evolve (if everything continues as it has been
so far), but they provide very limited insight into how frontline
doctors can fight the virus.
Epidemiological data often combine a limited number of
variables for substratification of cases; these data categorize
continuous variables for reporting purposes and often lack
detailed information on variables collected during hospital care.
Epidemiological curves do not allow us to answer clinical
questions such as what the most relevant risk factors are for
becoming infected, having symptoms, becoming seriously ill,
or dying. They also do not allow us to study which treatments
work better and what patient characteristics can influence the
success or failure of the treatments. These are the questions that
we need to answer to improve patient care and to rationalize
the use of resources when health systems are at the limit of their
capacities. These questions have not been answered
satisfactorily. On March 24, 2020, a senior intensive care unit
physician working in a big hospital in Madrid told the lead
author that, “We learn things about the disease as we go along
every day.” Two weeks later, on April 9, 2020, a colleague
working at a hospital affiliated with University College London
Hospitals said, “…is a new disease with a pathology and clinical
course that none of us know about.” In between these two
statements, thousands of patients have died or recovered from
SARS-CoV-2 infection in Spain, the United Kingdom, and
many other countries. It seems we hardly learned anything from
those patients since months later we continue to ask the same
clinical questions: what are the determinants for bad prognosis?
How do we best treat patients?
What Do We Need to Solve the Problem?
To answer clinical questions, we need clinical data from
individual patients. We need a database where the anonymous
clinical information of hospitalized patients with COVID-19
can be stored, curated, and made accessible to researchers. The
structure of the data set does not have to be very complex since,
for each patient, the disease involves basically a single hospital
episode that does not usually last more than 4-5 weeks. The
database would be continually fed with each hospital discharge.
Statistical models to answer each clinical question can be
programmed and automatically updated as more data come in.
In this way, we would have a continuous information system
growing with the epidemic and generating knowledge in real
time that could be fed back to the frontline doctors treating
patients. Therefore, the health system to fight the epidemic
would have two subsystems working together: a care subsystem
to treat patients and a knowledge subsystem to learn about the
disease. This is what the literature has described as a learning
health system [3,4].
Although it would be ideal to link up with the patient’s medical
history in specialized and primary care, this may not be
necessary to answer the most pressing clinical questions about
prognosis and the best therapeutic strategies. Initially, each
health system (country/nation/region) would implement its own
database including as many hospitals as possible although
sharing information between countries would be advantageous.
In addition, because the epidemic develops asynchronously in
different countries, what we can learn from the data in one
country can help to improve patient treatment in other countries.
What Is Being Done?
There are many private initiatives to create registries of patients
with COVID-19 that include clinical data, some supported by
professional societies [5-14]. Although understandable and
praiseworthy, these initiatives are generally burdened with
problems:
1. Often these registries are disconnected from the electronic
health records of hospitals and require extra effort from
health care professionals to input the data. This has long
been known to be a major barrier to usage [15]. These
professionals are likely to be heavily overloaded with work,
and many of them simply refuse to fill out another form.
2. Since some of these registries are for patients with a specific
disease (eg, atopic dermatitis) and they try to collect very
detailed patient data, entry forms can be lengthy and
detailed.
3. Since some of these data sets recruit only specific kinds of
patients, their analysis will only apply to certain
subpopulations.
4. Contribution to these data sets is voluntary, and the speed
at which they grow depends on many factors, such as how
many professionals they have managed to reach and
persuade to collaborate, how many patients with the specific
selection criteria are available, and how easy they are to
feed. For example, as of April 11, 2020, the LEOSS (Lean
European Open Survey on SARS-CoV-2 infected patients)
[8] reported having 642 collaborators involved from 165
centers, but only 770 patients enrolled. However, the
Intensive Care National Audit & Research Centre [6], a
long-standing registry, reported having captured 2621
COVID-19 admissions to the intensive care unit by April
4, 2020.
5. Many of these registries have been designed to collect data
that will be analyzed when the epidemic is over, and the
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research questions behind them are not always connected
to the needs of health providers at the front line. Many of
these analyses will not be timely enough to confront the
current epidemic, and it is unclear whether they will be
useful to deal with the next one. One cannot blame
clinicians treating patients if they do not put much interest
in filling these forms that will not result in immediate
tangible benefits to their patients. Those who do the work
need to see the benefits to be motivated to participate
[16-18].
Some governments and health institutions have implemented
important initiatives to share individual patient clinical data on
COVID-19. For example, the Mexican government, following
a policy of open data, has been sharing clinical data on all
COVID-19 cases since April 13, 2020, with a daily update of
the entire data set [19]. The Health Insurance Review &
Assessment Service of South Korea also intended to make
anonymized clinical data pertaining to patients with COVID-19
available [20]. One of the most comprehensive initiatives is the
OpenSAFELY project [21] in the United Kingdom, which
created a new secure analytics platform for electronic health
records in the National Health Service (NHS) to deliver urgent
results during the global COVID-19 emergency. This platform
includes not only patients with COVID-19 but almost any patient
registered in participating primary care practices (more than 24
million patients’ full pseudonymized primary care NHS records,
with more to follow). Their complete analytic software is open
for security review, scientific review, and reuse.
Although all these initiatives are laudable and valuable for
facilitating important research to be undertaken and even
breakthroughs to be made in the fight against the pandemic,
none of them are learning systems that are integrated within
health care systems. They have not been designed within the
health care system to answer specific health care questions. In
our view, a health learning system would work best when
integrated with the care services through a constant feedback
loop to respond as quickly as possible to the most pressing
clinical questions as mentioned above [22]. The OpenSAFELY
platform is aiming to comply with this model although it was
not actually created within the NHS as an integral part of it but
by academics in universities who saw the potential of making
these data available to researchers outside the NHS who were
eager to help in the fight against the pandemic.
What Can Be Done?
The health systems should plan the collection, availability,
analysis, and reporting of clinical data in a timely manner that
can effectively influence the response to the epidemic. That is,
they should strive to become learning health systems during the
epidemic. We offer some suggestions to achieve this.
1. Design
There should be protocols to ensure that at least a minimum set
of relevant clinical variables are collected using the same criteria
and procedures across all units of a health system. Failure to
regulate and standardize clinical data collection might lead to
the development of several independent data sets that are not
easy to link to one another. Interoperability solutions are vital
[23]. It is not our purpose here to propose a specific set of
variables for the COVID-19 pandemic; we believe this should
be agreed upon by appointed expert panels, but below we point
out some important considerations that should be addressed
when designing the database.
Scope
The database should be designed in such a way that it can be
implemented in most health units expected to collect the data.
In general, the more heterogeneous the data collectors, the
simpler the database will need to be to maximize the possibility
of collecting comparable data across units. For example, if a
supranational organization such as the World Health
Organization (WHO) were to suggest a data structure, it is
advisable to keep the specifications as simple as possible to be
applicable to most countries, bearing in mind the diversity of
health systems and resources available. In contrast, a country
with a highly digitalized and homogeneous health system can
specify a more complex data structure. The advantages of the
WHO approach would be to potentially collect a much larger
data set covering diverse populations in different countries,
while a country-specific model could collect less but more
detailed data. A combination of the two approaches might be
possible with the WHO producing a data structure with different
layers of complexity starting from a top, simpler level collecting
the most basic data to answer the most pressing questions down
to levels of highly complex data. Each health system could then
try to achieve as many levels as possible depending on their
capabilities.
Objectives
It is important to design the data collection process with a
specific research question(s) in mind to determine how and what
data should be collected. For example, to answer the question
“what risk factors affect the probability of infection?” we might
want to collect information on the patient’s circumstances
(social, family, and work) before and around the infection time,
but to answer the question “what conditions determine poor
progression after hospital admission?” it might be enough to
collect clinical information at hospital admission. A question
about treatment effectiveness will require health services to
collect detailed information on treatments and all potential
confounding factors. In general, the more questions we want to
answer, the more data we need to capture and the more complex
the system will be.
Costs
Obtaining each piece of information bears a cost. Sometimes
this is minimal (eg, when information is collected routinely in
the health system and easily retrievable) or it can require
specialized resources and personnel who might not be available.
Costly and complex information is more likely to not be properly
collected in a system already under stress. Information partially
and poorly collected is a potential source of bias if included in
the analysis, and it might be therefore better to ignore it
altogether. Hence, the costs and benefits of the information must
be carefully balanced to reduce waste of resources, time, and
the potential for bias.
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The benefit of variables is their potential contribution to answer
one or more of the research questions. This does not mean that
we can only include in the database variables that we know in
advance to have some explanatory power for the outcomes that
we want to study; in fact, we will not know this until we analyze
the data after collection. However, there must be some
reasonable expectations that the variable has an explanatory
role or is a potential confounder that we need to adjust for in
the analysis. The potential benefits must outweigh the costs of
collecting and processing the information. Collecting variables
with a priori limited expected explanatory power just in case
someone finds a good use for them in the future is not a wise
strategy when answers need to be found quickly. Apart from
the extra cost of collection and processing, more statistical
models might need to be run to confirm whether those variables
are indeed irrelevant. This can unnecessarily increase the
chances of finding false-positive associations that might divert
efforts and attention from exploring the important causal
associations [24].
In summary, a combined panel of experts with knowledge of
the specific disease, epidemiology, health information systems,
and statistics should design a database structure to answer a
specific set of questions, considering the cost/benefit balance
of the information to be collected, bearing in mind who is going
to collect the data, and possibly proposing several layers of data
collection from a minimum, simpler-to-collect set of variables
to more complex data structures for highly digitalized systems.
2. Plan
A good plan will fail if the means to execute it are not made
available. Technology can facilitate the collection of data. Where
good electronic health records exist, relevant clinical data can
be extracted from them. The particular implementation will
depend on the characteristics of each health system and the data
to be collected as defined in the Design section. For example,
if a health system is highly informatized and most of the required
data are already collected in electronic health records routinely,
then perhaps only a database operator is needed to extract the
relevant data. If the health system’s information is mainly on
paper, a team of dedicated researchers with a sufficient medical
background will need to be recruited to extract the data and
input the information into an electronic format. We cannot
specify here what kind of professionals need to be hired or
reinforced in each health system, but we can provide some points
that should be considered to define needs:
• Consider the level of medical/epidemiological knowledge
needed for the personnel involved in data extraction;
• Consider the technical difficulties of data extraction,
storage, and curation, as well as knowledge of information
technology and informatics needed to do this;
• Consider the complexity of the statistical analyses to be
done with the data.
The golden rule is that these processes should not burden and
distract care providers from their main job—treating the patients.
Similar to how extra teams of doctors and nurses were brought
in to care for patients on the frontline, and mathematical
modelers were recruited to predict the progression of the
epidemic, experts in medical informatics and data analysis
should also be recruited to help analyze the clinical data on a
nearly daily basis.
3. Integrate
Protocols permitting the two subsystems, care provision and
data analysis, to work in synchrony need to be established [22].
The care system will provide data and the relevant questions,
and the analysis system will run statistical and computer models
to try to answer those questions. The findings will then be fed
back to the care system, which can revise its strategy in light
of new evidence. In the initial stages of the epidemic, clinical
questions can be formulated, and the analysis team can design
Bayesian models using existing prior clinical and biological
knowledge. Once data start accumulating, the Bayesian models
will be updated, and they can be used for decision making.
The kind of study designs that can be implemented in a learning
health system can vary from simple case reports to randomized
clinical trials, and one can potentially do several designs in
parallel [25]. For example, a cohort analysis can be set up to
look at risk factors at the diagnosis point for disease progression,
so that patients can be triaged more efficiently at overloaded
hospital admission departments. At the same time, if clinicians
had clinical equipoise of treatment options for a subgroup of
patients, a registry-based randomized clinical trial could be set
up to decide the best treatment options in a timely manner
[26-28]. In large health systems that cover most of the
population, cases can be captured rather quickly if the learning
system is implemented and coordinated across sites (hence the
need for regulating and standardizing the methods).
4. Enforce
Data collection should not be regarded as an optional task in an
epidemic as it is a necessary resource to learn how to fight the
epidemic more effectively, to guarantee the right of the patient
to the best possible care, and to reduce the number of deaths.
The term “enforcement” might have negative connotations when
related to health care research where we expect that participation
of both researchers and patients should always be voluntary.
However, a pandemic is an exceptional situation where the
health (and possibly survival) of the population is at serious
risk, and the public good must be balanced against individual
rights. This is indeed the case when restrictions such as
quarantines or curfews are imposed during pandemics.
Enforcement is much more likely to work if care professionals
and patients are willing to collaborate. Early engagement
through appropriate communication with health professionals
and the public is explained below.
5. Engage Health Professionals
Collaboration as early as possible with clinical users is key to
ensure these systems are usable and useful and to encourage
adoption [3,18,23]. Cooperation of clinical users is not only key
to ensuring good data quality; they also have to produce relevant
clinical questions and incorporate the new knowledge generated
into their practice. For care providers to spend time and energy
engaging with the system, they must see it as an investment that
will benefit their work and their patients rather than another
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administrative burden. It is crucial that they are involved in the
design of the system to ensure that the system meets their needs
and to facilitate trust in the system.
6. Inform the Population
Plans need to be made to address concerns around patient
privacy and confidentiality [23], including appropriate legislative
frameworks for emergency situations. In particular, ethical
issues around data usage for research, by people inside and
outside the system, need to be tackled from the beginning. In a
setting of an infectious epidemic, it might be impossible to
obtain informed consent from every single patient for their data
to be used for research purposes. There are also procedures by
which a priori one presumes consent of a patient who is unable
to provide it in a critical situation, and later this consent is
confirmed when the patient recovers or through relatives, and
the data can be pulled out of the study if consent is revoked.
These procedures have been implemented successfully in
randomized clinical trials of emergency treatments [29].
On the other hand, these data are urgently needed to learn as
quickly as possible about the disease, to stop the epidemic, and
to save lives. The right to confidentiality should be balanced
against urgency to control the epidemic. Data for research should
be anonymized as much as possible. Ideally, an anonymized
data set would have the ethical approval to be freely used for
research in such a way that individual researchers would not
have to seek approval separately for each project that uses the
same data.
7. Share
Data should be made available to external researchers, and
administrative burden should be reduced. Often, research
projects in traditional settings have to go through tedious
administrative procedures, seeking approval from different
committees on different aspects such as ethics, technical quality,
economic viability, chances of success, etc. This can delay data
acquisition, analysis, and generation of results by weeks or
months that might cost thousands of lives during an epidemic.
Within a learning health system that sets up its own analysis
teams, which are well coordinated with clinical teams, as
specified in the Plan section, most of these requirements should
be removed, so that the analysis can be done efficiently in real
time in house. However, the system should also consider
opening its data (anonymized as required) to external
researchers. The health system could then benefit from the brain
power of thousands of teams that might be able to tackle many
problems simultaneously from different angles. For example,
in the current COVID-19 epidemic, there have been thousands
of highly qualified researchers literally locked at home, willing
to help, and eager to analyze clinical data. Health systems might
not have the capacity and resources to recruit, incorporate, and
coordinate all these groups into their internal structure, but they
might benefit from their ideas and skills if they provided them
with data and research questions. This could render benefits to
the health system, the scientific community, and society as a
whole. However, to allow these groups to provide answers
quickly, administrative procedures should be simplified as much
as possible. For example, if adequately anonymized data sets
are created and approved for external research by an ethics
committee of the health system, they can be made freely
accessible and readily usable to external researchers without
having each of them apply and wait for ethics approval.
In the current COVID-19 epidemic, most of the registries
mentioned above have tried to implement this model. However,
to make the data accessible, they still require the potential
researcher to present a project that has to be evaluated by an
expert committee before the data can be released. The
consequence of this policy is to produce a bottleneck of project
approvals that delays necessary research. Paradoxically, the
more relevant the data of the registry and the larger the potential
research community, the bigger the bottleneck is likely to be
(unless more resources are put into place to manage requests).
Is not always clear what the purpose of this step is. New ethical
approval should not be necessary if the data are correctly
anonymized and ethically approved already. Often the argument
is to act as a gatekeeper against potential “bad science” practices.
However, the gate keeping can be done a posteriori by the
scientific community by looking at the outputs of the research,
as it is normally done for peer-reviewed publication or preprints.
This will not delay the finding of potentially important results.
It would certainly be encouraged to avoid publication bias by
making all research available even if results are not positive or
conclusive, but this can be solved through setting up a registry
of protocols (similar to, for example, ClinicalTrials.gov [30])
that does not create a bottleneck neck and delay research.
8. Revise and Update
A health learning system is not a one-off exercise in design. It
should be a life system constantly adapting itself to a changing
environment [22], especially during epidemics where the
situation is expected to change rapidly. There should be a
permanent committee made up of clinicians, epidemiologists,
health care system experts, medical informatic experts, and
statisticians, who will supervise (daily if needed) the functioning
of the system and steer the necessary changes. The committee
should check, on a long-term basis, if:
• The system is doing what it was designed to do, that is,
collect the right data, perform the planned analysis, and
answer the questions that were asked);
• The outcomes from the learning system are having an
impact on health care decisions and outcomes (ie, assess
whether there is a connection between the two systems);
• Any new questions need to be answered as the epidemic
evolves. If yes, determine how the learning system should
be adapted to address them.
Conclusions
This paper is a reflection on the lack of a strategy involving
learning health systems, which is proving to be a critical
shortcoming of the current health care systems’ ability to fight
the pandemic. It is also a proposal of points that need to be
considered for implementation and integration, such as learning
systems within the health care system. Different countries may
need to apply different strategies to organize and implement a
system to collect, analyze, and disseminate results and relevant
information in a timely fashion. Those strategies will depend
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on health governance, and, in particular, on how health systems
are structured around a unique legal and administrative body.
However, as a scientific community, we need to change the way
we think about clinical data and clinical research in epidemics.
Clinical data should be valued not only as an information source
for the patient who has generated it but also as the main resource
for learning about the disease and saving the next patient.
Clinical research should not be considered an academic activity
to be done once the epidemic is over; it should be viewed as
the main way of learning from clinical data and be completed
as close as possible in time during clinical practice while the
epidemic is ongoing and with the fastest possible feedback
between the two activities (care and research).
Perhaps the most compelling evidence that we are doing things
wrong is the actual macro figures of the COVID-19 epidemic.
As of today, with over 117 million confirmed cases around the
world and deaths approximating the 3-million mark, we are still
asking many of the clinical questions that we were asking in
the beginning. We hope that this piece acts as a wake-up call
on this issue.
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